{"filing":{"accession_number":"0001213900-26-098595","cik":"0001584371","ticker":"ICCM","company_name":"IceCure Medical Ltd.","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"ea0305096-6k_icecure.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1584371/000121390026098595/ea0305096-6k_icecure.htm"},"events":[{"id":32572,"run_id":29930,"accession_number":"0001213900-26-098595","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"IceCure Medical announced receipt of regulatory approval from China's National Medical Products Administration (NMPA) to market its ProSense® cryoablation system as a Class III medical device. This is a material operational and regulatory milestone that expands the company's addressable market and commercialization opportunities in China, a major healthcare market. While not fitting the specific categories of M\u0026A, litigation, or financial events, this regulatory clearance is a significant business development that would affect a reasonable investor's assessment of the company's growth prospects and market access.","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":35773,"accession_number":"0001213900-26-098595","item_number":"EX-99.1","item_title":"ea030509601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"IceCure Medical announced receipt of regulatory approval from China's National Medical Products Administration (NMPA) to market its ProSense® cryoablation system as a Class III medical device. This is a material operational and regulatory milestone that expands the company's addressable market and commercialization opportunities in China, a major healthcare market. While not fitting the specific categories of M\u0026A, litigation, or financial events, this regulatory clearance is a significant business development that would affect a reasonable investor's assessment of the company's growth prospects and market access.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:52:37.871149+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35773,"accession_number":"0001213900-26-098595","item_number":"EX-99.1","item_title":"ea030509601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"IceCure Medical announced receipt of regulatory approval from China's National Medical Products Administration (NMPA) to market its ProSense® cryoablation system as a Class III medical device. This is a material operational and regulatory milestone that expands the company's addressable market and commercialization opportunities in China, a major healthcare market. While not fitting the specific categories of M\u0026A, litigation, or financial events, this regulatory clearance is a significant business development that would affect a reasonable investor's assessment of the company's growth prospects and market access.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:52:37.871149+00:00","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-09-10"}]}